免疫细胞在特发性肺纤维化中的研究进展

Progress of Immunocyte in Idiopathic Pulmonary Fibrosis

特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是慢性进展性肺间质疾病,其发病率呈逐年上升趋势,且预后差、病死率高。现有指南仅推荐尼达尼布和吡非尼酮用于IPF治疗,但二者均因价格昂贵导致临床应用受限。虽然IPF发病机制至今未完全阐明,但是免疫细胞及其相互作用在IPF发病中起着重要作用。本文结合近年来研究热点,通过总结分析IPF相关的免疫细胞作用机制及相关药物研究,为进一步探索免疫治疗提供参考。

Idiopathic pulmonary fibrosis（IPF） belongs to chronic progressive interstitial lung disease. The morbility of IPF is increasing with poor prognosis and high mortality year by year. At present, Nintedanib and Pirfenidone have been only recommended by guideline, however both are limited in clinical application because of their high price. The pathogenesis of IPF is not entirely clear. However, immune cells and their interactions play an important role in the pathogenesis of IPF. In this review, it is summarized the function mechanism of immune cells and related medicines of IPF in order to provid basis for further exploration of immunotherapy.